Improving targeted therapy for neuroendocrine tumors while protecting kidney health
Official title: Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
Funded at Research Inst Nationwide Children's Hosp · NIH-10942787 · Data updated 2026-11-12
This study is looking at a new treatment for neuroendocrine tumors that uses special targeted therapy to help shrink tumors while protecting your kidneys, so you can get a safer and more effective plan tailored just for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $627,573 |
| NIH project number | 1R01CA291827-01 |
| Project ID | NIH-10942787 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with neuroendocrine tumors who are considering or undergoing alpha-emitter radioligand therapy.
✕Less likely to help
Patients with neuroendocrine tumors who are not eligible for radioligand therapy or those with pre-existing severe kidney conditions may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of a new type of targeted therapy for neuroendocrine tumors (NETs) that uses alpha-emitting radioligands. The approach aims to maximize tumor response rates while minimizing kidney damage, which can occur as a side effect of treatment. By investigating biomarkers of kidney injury and optimizing dosing regimens, the study seeks to develop a safer and more effective treatment protocol. Patients may benefit from a more personalized treatment plan that considers both tumor response and kidney health.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with neuroendocrine tumors while reducing the risk of kidney damage.
How similar studies have gone: Other research has shown promising results with similar targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Zepeda-Orozco, Diana — Research Inst Nationwide Children's Hosp
- Study coordinator: Zepeda-Orozco, Diana
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Enteric glial cell reprogramming and MENIN loss in dpNETs
A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.
-
Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy
Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.
-
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors
A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.